Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
The protocol received approval from the Danish Medicines Agency (2019083844) and Central Denmark Region Committees on Health Research Ethics (1-10-72-195-19). The study is registered in the European Union Drug Regulating Authorities Clinical Trials Database (EudraCT: 2019-002665-35). The study was monitored by the Good Clinical Practice unit at Aarhus and Aalborg University Hospitals. Written and oral informed consent from all participating individuals were obtained.
1. Introduction Low success rates in drug development for psychiatric and neurological diseases can in part be attributed to an inadequate understanding of the intricate mechanisms and underlying molecular correlates that go awry in these diseases in vivo, and the dynamic complex nature of mental components such as cognition and emotion.
Abstract Carboxypeptidase II (CBPII) in brain metabolizes the neuroactive substance N-acetyl-L-aspartyl-L-glutamate (NAGG) to yield the elements of glutamate and N-acetyl-aspartate (NAA). In peripheral organs, CBPII is known as prostrate specific membrane antigen (PSMA), which presents an important target for nuclear medicine imaging in prostate cancer.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
